Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2019
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with MyelofibrosisRoni Tamari, Franck Rapaport, Nan Zhang, et al.
Nature Medicine|December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trialJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
The Lancet. Haematology|December 9, 2022
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMTNicola Polverelli, Juan Carlos Hernández-Boluda, Tomasz Czerw, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRuben Mesa, Catriona Jamieson, Ravi Bhatia, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
The Lancet. Haematology|July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 studyAaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
Blood|February 29, 2020
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosisLukas Ronner, Nikolai Podoltsev, Jason Gotlib, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with MyelofibrosisJohn Mascarenhas, Anna Rita Migliaccio, Heidi Kosiorek, et al.
The Lancet. Haematology|November 5, 2025
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 studyRuben Mesa, Harinder Gill, Lei Zhang, et al.
Pageof 18